)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Syros Pharmaceuticals (SYRS) investor relations material
Syros Pharmaceuticals Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary31 Oct, 2024
Executive summary
Advancing tamibarotene as a potential new standard for frontline treatment of higher risk MDS patients with RARA overexpression, representing about 50% of this population.
Pivotal SELECT-MDS-1 Phase 3 trial in higher-risk MDS nearing a key data readout in mid-November 2024.
Company discontinued SELECT-AML-1 enrollment and prioritized tamibarotene after a 2023 restructuring and cost reduction.
No product sales revenue; operations funded by equity, debt, and collaborations.
Significant commercial opportunity with U.S. higher risk MDS therapeutics market projected at $1.6B by 2029 and tamibarotene's addressable market over $800M.
Financial highlights
Cash and equivalents were $58.3M as of September 30, 2024, expected to fund operations into Q3 2025.
Net loss for Q3 2024 was $6.4M, down from $40.1M in Q3 2023; net loss for the nine months ended September 30, 2024 was $33.4M, down from $100.2M in the prior year.
R&D expenses for Q3 2024 were $20.5M, down from $28.3M in Q3 2023; G&A expenses for Q3 2024 were $5.7M, down from $7.8M.
No revenue recognized in Q3 or first nine months of 2024, compared to $3.8M and $9.6M in 2023 from a terminated collaboration.
Gain from change in fair value of warrant liabilities was $20.3M in Q3 2024, reflecting a decrease in stock price.
Outlook and guidance
SELECT-MDS-1 pivotal data readout in mid-November will focus on complete response rate and safety; overall survival data to follow.
NDA filing for tamibarotene planned post-data, with regulatory processes on track and no unusual requirements anticipated.
Commercial launch preparations underway, including market education, infrastructure, and manufacturing readiness.
Management is pursuing additional capital through equity, debt, or business development, but success is not guaranteed.
Substantial additional funding required to continue operations beyond Q3 2025.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Syros Pharmaceuticals Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company uses its proprietary gene control platform to identify and develop small-molecule drugs that modulate the expression of specific genes associated with disease. Syros's pipeline includes investigational treatments for hematologic cancers, solid tumors, and other genetically defined diseases. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage